<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02957552</url>
  </required_header>
  <id_info>
    <org_study_id>MYSTEP1</org_study_id>
    <secondary_id>2014-003561-15</secondary_id>
    <nct_id>NCT02957552</nct_id>
  </id_info>
  <brief_title>Safety and Tolerance of Immunomodulating Therapy With Donor-specific MSC in Pediatric Living-Donor Liver Transplantation</brief_title>
  <acronym>MYSTEP1</acronym>
  <official_title>Safety and Tolerance of Immunomodulating Therapy With Donor-specific Mesenchymal Stem Cells in Pediatric Living-Donor Liver Transplantation, a 24-month, Non-randomized, Open-label, Prospective, Single-center Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since the introduction of calcineurin-based immunosuppression, patient and graft survival in
      pediatric liver transplantation (LT) improved significantly. However, in contrast,
      calcineurin inhibitor (CNI) toxicity leads to significant morbidity and impairs quality of
      life for recipients. Moreover, CNI cannot prevent long-term allograft inflammation and
      fibrosis.

      Mesenchymal stem (stromal) cells (MSC) have potent immunomodulatory properties potentially
      promoting allograft tolerance and ameliorating toxicity of exposure to high dose CNI.
      Previous trials for non-solid organ transplant indications have shown an excellent safety
      profile of intravenous MSC application. The MYSTEP1 trial aims to investigate safety and
      benefits portal and intravenous MSC infusion in pediatric LT.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with MYSTEP-score grade 3 and grade 2 (toxicity of MSC infusion)</measure>
    <time_frame>28 days</time_frame>
    <description>In order to evaluate and quantifiy acute clinical complications related to MSC infusion, the investigators defined the MYSTEP score, a specific pediatric infusional toxicity scoring system (adapted from MiSOT-I score). The score focusses on description of intraportal, pulmonary and systemic toxicity. For each of these three modalities, degrees of severity between 0 (no treatment emergent adverse event) and 3 (severe treatment emergent adverse event) have been defined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with occurrence of any severe adverse events (SAE)</measure>
    <time_frame>Two years</time_frame>
    <description>A particular focus will be on viral infections and reactivation (ADV, HCMV, EBV, Hepatitis B, Hepatitis C and Hepatitis E), bacterial or fungal infections.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Graft function after liver transplantation - Number of participants with abnormal liver tests</measure>
    <time_frame>Two years</time_frame>
    <description>Graft function after liver transplantation, measured by aminotransferase and gamma glutamyl transferase activity, bilirubin, albumin and INR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Individual need for immunosuppressive medication</measure>
    <time_frame>Two years</time_frame>
    <description>measured by tacrolimus trough levels [ng/ml] and prednisolon dosage [mg/kgBW/day]. Tapering of tacrolimus and steroids will be performed according to a step-wise tapering protocol after day 180.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first biopsy-proven acute rejection (BPAR)</measure>
    <time_frame>Two years</time_frame>
    <description>Protocol liver biopsy will be performed on day 180 post LT. Additional biopsies will be taken whenever clinically necessary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune monitoring: donor-specific antibodies (DSA)</measure>
    <time_frame>Two years</time_frame>
    <description>[Participants with positive DSA]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient and graft survival at 1 and 2 years after liver transplantation</measure>
    <time_frame>up to Two years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">7</enrollment>
  <condition>Pediatric Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>Treatment with Mesenchymal Stem Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two doses of 1 x 10^6 MSCs/kg body weight:
first administration intraoperatively via intraportal infusion
second infusion via intravenous infusion on postoperative day 2 (+/- 1 day)
Standard immunosuppressive treatment consisting of steroids, basiliximab and tacrolimus according to the center's pediatric liver transplantation protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mesenchymal Stem Cells</intervention_name>
    <description>Donor-specific, bone marrow derived mesenchymal stem (stromal) cells</description>
    <arm_group_label>Treatment with Mesenchymal Stem Cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent (patients, both parents and / or legal guardian)

          2. age ≥ 8 weeks and ≤ 18 years

          3. undergoing living donor liver transplantation for chronic terminal liver failure

          4. Body weight &gt; 5kg

        Exclusion Criteria:

          1. No suitability of the living-donor

          2. Pregnant or breastfeeding

          3. If appropriate: no use of adequate contraception

          4. Acute liver failure; highly urgent transplantations

          5. Receiving any form of solid organ retransplantation

          6. Multi-Organ-Transplantations

          7. Active autoimmune disease

          8. Pre-existing renal failure with eGFR &lt; 50 ml/min/1.73 m2 or requiring hemodialysis

          9. Reduced pulmonary function (lung function test in children older than 6 years: FEV1
             and FVC &lt; 70% of age-appropriate norm) or clinical suspicion of pulmonary disease
             affecting patient's physical performance, requiring invasive or non-invasive
             mechanical ventilation.

         10. History of pulmonary embolism

         11. Pulmonary hypertension and / or right ventricular load in echocardiography

         12. Cardiac function: left ventricular shortening fraction (FS) &lt; 25%

         13. Clinically significant systemic infections

         14. Critical care treatment like mechanical ventilation, dialysis or vasopressor agents.

         15. HIV seropositive, HTLV seropositive, Hepatitis B/C seropositive

         16. Hepato-biliary malignancies or history of any extra-hepatic malignancy

         17. Thrombophilia

         18. Budd-Chiari syndrome

         19. Pre-existent thrombosis of portal vein

         20. Doppler-sonographic evidence for relevant porto-systemic shunts, like persistent
             Ductus Venosus

         21. Cold ischemia time &gt; 90 min

         22. Known abuse for drugs or alcohol

         23. Known allergy to DMSO
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Weeks</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ekkehard Sturm, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Tuebingen, Germany; Dept. for Pediatric Gastroenterology and Hepatology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steffen Hartleif, MD</last_name>
    <phone>+49-7071-29-0</phone>
    <phone_ext>81339</phone_ext>
    <email>steffen.hartleif@med.uni-tuebingen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steffen Hartleif, MD</last_name>
      <phone>+497071-29</phone>
      <phone_ext>84711</phone_ext>
      <email>steffen.hartleif@med.uni-tuebingen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2016</study_first_submitted>
  <study_first_submitted_qc>November 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2016</study_first_posted>
  <last_update_submitted>June 18, 2017</last_update_submitted>
  <last_update_submitted_qc>June 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Dr. Ekkehard Sturm (MD, PhD)</investigator_full_name>
    <investigator_title>Head of Pediatric Gastroenterology and Hepatology</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

